Cancer Microenvironment

, Volume 11, Issue 2–3, pp 115–124 | Cite as

Ascites IL-10 Promotes Ovarian Cancer Cell Migration

  • Denis Lane
  • Isabelle Matte
  • Perrine Garde-Granger
  • Paul Bessette
  • Alain PichéEmail author
Original Article


Ovarian cancer (OC) ascites is an inflammatory and immunosuppressive tumor environment characterized by the presence of various cytokines, chemokines and growth factors. The presence of high concentrations of these cytokines/chemokines in ascites is associated with a more aggressive tumor phenotype. IL-10 is an immunosuppressive cytokine for which high expression has been associated with poor prognosis in some cancers. However, its role on OC tumor cells has not been explored. Therefore, the aim of the current study was to elucidate the role of ascites IL-10 on the proliferation, migration and survival of OC cell lines. Here, we show that IL-10 levels are markedly increased in patients with advanced serous OC ascites relative to serous stage I/II ascites and peritoneal effusions from women with benign conditions. Ascites and IL-10 dose-dependently enhanced the proliferation and migration of OC cell lines CaOV3 and OVCAR3 but had no effect on cell survival. IL-10 levels in ascites positively correlated with the ability of ascites to promote cell migration but not proliferation. Depletion of IL-10 from ascites markedly inhibited ascites-induced OC cell migration but was not crucial for ascites-mediated cell proliferation. Taken together, our findings establish an important role for IL-10, as a component of ascites, in the migration of tumor cells.


Ovarian carcinoma Ascites IL-10 Cell migration Cell proliferation 



This work was supported by funds from the Canadian Institute for Health Research (MOP-244194-CPT-CFDA-48852), the Centre de Recherche Clinique Étienne-Lebel du Centre Hospitalier Universitaire de Sherbrooke and the Université de Sherbrooke. Tumor banking were supported by the Banque de tissus et données of the Réseau de recherche sur le cancer of the Fond de recherche du Québec en Santé (FRQS) and Cancer de l’Ovaire Canada, associated with the Canadian Tumor Repository Network (CTRNet). The tissue bank provided malignant ascites and peritoneal fluids.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Supplementary material

12307_2018_215_MOESM1_ESM.ppt (266 kb)
ESM 1 (PPT 265 kb)


  1. 1.
    Bast RC, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428CrossRefPubMedGoogle Scholar
  2. 2.
    Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC (2004) Focus on epithelial ovarian cancer. Cancer Cell 5:19–24CrossRefGoogle Scholar
  3. 3.
    Shen-Gunther J, Mannel RS (2002) Ascites as a predictor of ovarian malignancy. Gynecol Oncol 87:77–83CrossRefPubMedGoogle Scholar
  4. 4.
    Ayhan A, Gultekin M, Taskiran C, Dursun P, Firat P, Bozdag G, Celik NY, Yuce K (2007) Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 17:68–75CrossRefGoogle Scholar
  5. 5.
    Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945–949CrossRefPubMedGoogle Scholar
  6. 6.
    Matte I, Lane D, Laplante C, Rancourt C, Piché A (2012) Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2:566–580PubMedCentralPubMedGoogle Scholar
  7. 7.
    Lane D, Matte I, Rancourt C, Piché A (2011) Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 11:210CrossRefPubMedGoogle Scholar
  8. 8.
    Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M (2009) Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 29:2875–2884Google Scholar
  9. 9.
    Maccio A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58:133–147CrossRefGoogle Scholar
  10. 10.
    Germano G, Allavena P, Mantovani A (2008) Cytokines as a key component of cancer-related inflammation. Cytokine 43:374–379CrossRefGoogle Scholar
  11. 11.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefPubMedGoogle Scholar
  12. 12.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444CrossRefPubMedGoogle Scholar
  13. 13.
    Lane D, Robert V, Grondin R, Rancourt C, Piché A (2007) Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt in human ovarian carcinoma cells. Int J Cancer 121:1227–1237CrossRefGoogle Scholar
  14. 14.
    Lane D, Goncharenko-Khaider N, Rancourt C, Piché A (2010) Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 29:3519–3531CrossRefGoogle Scholar
  15. 15.
    Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A (2012) Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer 11:84CrossRefPubMedGoogle Scholar
  16. 16.
    Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM (2007) Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 9:820–829CrossRefPubMedGoogle Scholar
  17. 17.
    Matte I, Lane D, Laplante C, Garde-Granger P, Rancourt C, Piché A (2015) Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and –independent mechanisms. Int J Cancer 137:289–298CrossRefGoogle Scholar
  18. 18.
    Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367:103–107CrossRefGoogle Scholar
  19. 19.
    Jankovic D, Kugler DG, Sher A (2010) IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol 3:239–246CrossRefPubMedGoogle Scholar
  20. 20.
    Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M, Wynn TA, Kamanaka M, Flavell RA, Sher A (2007) Conventional T-bet(+) Foxp3(−) Th1 cells are the major source of host protective regulatory IL-10 during intracellular protozoan infection. J Exp Med 204:273–283CrossRefPubMedGoogle Scholar
  21. 21.
    Maynard CL, Weaver CT (2008) Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 226:219–233CrossRefPubMedGoogle Scholar
  22. 22.
    Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76CrossRefGoogle Scholar
  23. 23.
    Umetsu SE, Winandy S (2009) Ikaros is a regulator of Il10 expression in CD4+ T cells. J Immunol 183:5518–5525CrossRefPubMedGoogle Scholar
  24. 24.
    Li C, Li H, Jiang K, Li J, Gai X (2014) TLR4 signaling pathway in mouse Lewis lung cancer cells promotes the expression of TGF-β1 and IL-10 and tumor cells migration. Biomed Mater Eng 24:869–875Google Scholar
  25. 25.
    Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH (1993) Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55:96–101CrossRefGoogle Scholar
  26. 26.
    Krüger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankenstein T, Diamantstein T (1994) Expression of interleukin 10 in human melanoma. Br J Cancer 70:1182–1185CrossRefPubMedGoogle Scholar
  27. 27.
    Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, Gardeazabal J, Bilbao J, Canavate M, Galdeano AG, Izu R, Diaz-Ramon L, Raton JA, Diaz-Perez JL (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 83:847–852CrossRefPubMedGoogle Scholar
  28. 28.
    Chen Q, Daniel V, Maher DW, Hersey P (1994) Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer 56:755–760CrossRefGoogle Scholar
  29. 29.
    Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D (2001) Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Investig 19:239–247CrossRefGoogle Scholar
  30. 30.
    Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383–1390PubMedGoogle Scholar
  31. 31.
    Boulland ML, Meignin V, Leroy-Viard K, Copie-Bergman C, Brière J, Touitou R, Kanavaros P, Gaulard P (1998) Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas. Am J Pathol 153:1229–1237CrossRefPubMedGoogle Scholar
  32. 32.
    Nowark M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J (2010) Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 31:375–383Google Scholar
  33. 33.
    Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O (1992) Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4:385–390CrossRefPubMedGoogle Scholar
  34. 34.
    Mustea A, Konsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J (2006) Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res 26:1715–1718Google Scholar
  35. 35.
    Berger S, Siegert A, Denkert C, Kobel M, Hauptmann S (2001) Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother 50:328–333CrossRefPubMedGoogle Scholar
  36. 36.
    Zhou J, Ye F, Chen H, Lv W, Gan N (2007) The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35:290–300CrossRefGoogle Scholar
  37. 37.
    Brencicova E, Jagger AL, Evans HG, Georgouli M, Laios AH, Montalto S, Mehra G, Spencer J, Ahmed AA, Raju-Kankipati S, Taams LS, Diebold SS (2017) Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on toll-like receptor-mediated dendritic cell activation in ovarian carcinoma. PLoS One 12:e0175712CrossRefPubMedGoogle Scholar
  38. 38.
    Lamichhane P, Karyampudi L, Shreeder B, Krempski J, Bahr D, Daum J, Kalli KR, Goode EL, Block MS, Cannon MJ, Knutson KL (2017) IL10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer. Cancer Res 77:6667–6678CrossRefGoogle Scholar
  39. 39.
    Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249–256CrossRefPubMedGoogle Scholar
  40. 40.
    Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piché A (2016) CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer 15:58CrossRefPubMedGoogle Scholar
  41. 41.
    Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H (2017) Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR−/low myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget 8:76843–76856PubMedCentralPubMedGoogle Scholar
  42. 42.
    Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I, Ozawa K (2003) Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091–5094Google Scholar
  43. 43.
    Deying W, Feng G, Shumei L, Hui Z, Ming L, Hongqing W (2017) CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep 37:BSR20160470CrossRefPubMedGoogle Scholar
  44. 44.
    Goldsmith ZG, Ha JH, Jayaraman M, Dhanasekaran DN (2011) Lysophosphatidic acid stimulates the proliferation of ovarian Cancer cells via the gep proto-oncogene Gα(12). Genes Cancer 2:563–575CrossRefPubMedGoogle Scholar
  45. 45.
    Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC (2012) Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 59:228–236CrossRefGoogle Scholar
  46. 46.
    Yousif NG (2014) Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int 38:85–91CrossRefGoogle Scholar
  47. 47.
    Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, Sun P, Huang S (2004) Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 64:4209–4217CrossRefGoogle Scholar
  48. 48.
    Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH (2011) IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 71:424–434CrossRefGoogle Scholar
  49. 49.
    Furukama S, Soeda S, Kiko Y, Suzuki O, Hashimoto Y, Watanabe T, Nishiyama H, Tasaki K, Hojo H, Abe M, Fujimori K (2013) MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res 33:4785–4790Google Scholar
  50. 50.
    Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, Lee H (2013) IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Cancer Res 19:4092–4103Google Scholar
  51. 51.
    Chen XD, Tang SX, Zhang JH, Zhang LT, Wang YW (2017) CIP2A, an oncoprotein, is associated with cell proliferation, invasion and migration in laryngeal carcinoma cells. Oncol Rep 38:1005–1012CrossRefGoogle Scholar
  52. 52.
    Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21:331–344CrossRefGoogle Scholar
  53. 53.
    Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev 13:273–282CrossRefGoogle Scholar
  54. 54.
    Rabinovich A, Medina L, Piura B, Huleihel M (2010) Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw 21:122–128Google Scholar
  55. 55.
    Yao V, Platell C, Hall JC (2004) Peritoneal mesothelial cells produce inflammatory related cytokines. ANZ J Surg 74:997–1002CrossRefGoogle Scholar
  56. 56.
    Alldredge J, Flies D, Higuchi T, Ma T, Adams SF (2014) Impaired interleukin-10 signaling and ovarian cancer growth in the peritoneal cavity. J Clin Oncol 32(15 suppl):e22094–e22094Google Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Denis Lane
    • 1
  • Isabelle Matte
    • 1
  • Perrine Garde-Granger
    • 2
  • Paul Bessette
    • 3
  • Alain Piché
    • 1
    Email author
  1. 1.Département de Microbiologie et InfectiologieUniversité de SherbrookeSherbrookeCanada
  2. 2.Département de PathologieUniversité de SherbrookeSherbrookeCanada
  3. 3.Service d’obstétrique et gynécologie, Département de Chirurgie, Faculté de MédecineUniversité de SherbrookeSherbrookeCanada

Personalised recommendations